ecancermedicalscience

Clinical Study

METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

31 Mar 2022
João Glasberg, Aley Talans, Thomás Rivelli Giolo, Débora Zachello Recchimuzzi, João Evangelista Bezerra Neto, Rossana Veronica Mendonza Lopez, Paulo Marcelo Gehm Hoff, Rachel P Riechelmann

Background: Preclinical studies have suggested that metformin has anti-tumour effects, likely due to blockage of mammalian target of rapamycin pathway through adenosine monophosphate-activated protein kinase and decreased insulin levels. A retrospective study showed that metformin added to everolimus to treat type 2 diabetes mellitus offered longer progression-free survival (PFS) in patients with pancreatic neuroendocrine tumours (NET).

Aim(s): To evaluate the efficacy and safety of metformin monotherapy in patients with advanced/metastatic well-differentiated NET (WD-NET) of gastroenteropancreatic (GEP) or pulmonary origin.

Patients and methods: Single-arm phase II trial of metformin 850 mg PO twice daily until progression or intolerance for patients with progressive metastatic well-differentiated GEP or pulmonary NET. The primary endpoint was disease control rate (DCR) by RECIST 1.1 at 6 months. Secondary endpoints were response rate, PFS, toxicity and variations in glycaemic profiles (glycaemia, glycated haemoglobin and peptide C and insulin) at baseline, at 30 and 90 days.

Results: From 2014 to 2019, 28 patients were enrolled: median age was 50 years; 84% had non-functional NET, 86% were of GEP origin and 62% had G2 NET. At the time of last follow-up, 26 patients had progression, with 13 (46%) presenting DCR at 6 months and a median PFS of 6.3 months (95% confidence interval: 3.2–9.3). There was no objective response, but one patient with refractory carcinoid syndrome had complete symptom relief, lasting for more than 5 years. Variations in glycaemic profiles were not associated with DCR at 6 months. Diarrhoea was the most common adverse event, being grade 3 or 4 in 10% of the cases.

Conclusion: Metformin monotherapy offers modest anti-tumour activity in well-differentiated GEP or lung NET.

Related Articles

Carlos A. Castaneda, Miluska Castillo, Joselyn Sanchez, Luis Bernabe, Katherin Tello, Nancy Suarez, Raul Alatrista, Ximena Quiroz-Gil, Alexandra Granda-Oblitas, Javier Enciso, Nathaly Enciso, Henry L Gomez
Somnath Roy, Sreejata Raychaudhuri, Bivas Biswas, Deepak Dabkara, Arnab Bhattacherjee, Sandip Ganguly, Joydeep Ghosh, Yesha Sandipbhai Patel, Souhita Pal, Jagriti Karmakar, Anindita Mitra, Sujoy Gupta
Natalia Camejo, Camila Montenegro, Dahiana Amarillo, Cecilia Castillo, Gabriel Krygier
Ghazal Tansir, Sameer Rastogi, Ekta Dhamija, Shamim Ahmed Shamim, Deepali Jain, Adarsh Barwad, Sunil Kumar, Rambha Pandey